Summary

Autologous stem-cell transplantation is a sort of transplantation in which a patient's undifferentiated or stem cells—cells that can develop into multiple types of cells—are removed, gathered, and then given back to the patient. Heart cells are rarely used to heal damage from heart attacks because hematopoietic stem cells, which are the progenitors of blood cells, are more frequently used in hematopoietic stem cell transplantation. Two types of stem cell transplantation exist: allogenic and autologous stem cell transplantation. Autogenic, autogenous, or auto-SCT are other names for autologous stem-cell transplantation.
The primary factor boosting the growth rate of the markets for autologous stem cell and non-stem cell based therapies is the increase in the prevalence of diabetes and cancer across all age groups. A noteworthy contributing aspect to the market's growth is the introduction of innovative autologous stem cell-based treatments in the field of regenerative medicine. In addition, the growing number of elderly individuals and the increased need for therapies mostly based on non-stem cells and autologous stem cells are the main factors that will propel the market's expansion. The market growth rate will be tempered by other important factors including improving reimbursement rules and rising healthcare awareness.
Moreover, the market expansion for autologous stem cell and non-stem cell based therapies would benefit from the sizable unexplored market in developing nations as well as the increase in research and development activities.
The market expansion will be hindered, therefore, by the high expense of autologous cellular therapies and the lack of new product developments in surgical sutures. The market for autologous stem cell and non-stem cell based therapies will face challenges from the growing demand for enhanced wound closure products and the scarcity of qualified personnel. Additionally, side effects from the medication, like diarrhoea, vomiting, nausea, hair loss, infertility, serious infections, and heart problems, would limit the market and slow down its expansion.



Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Autologous Stem Cell and Non-Stem Cell Based Therapies Market, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:


Autologous Stem Cell and Non-Stem Cell Based Therapies Market based on Type
• Autologous Stem Cells
• Autologous Non-Stem cells
Autologous Stem Cell and Non-Stem Cell Based Therapies Market based on Application
• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disease
• Orthopedic Diseases
• Other Applications
Autologous Stem Cell and Non-Stem Cell Based Therapies Market based on End user
• Hospitals
• Ambulatory Surgical Centers
• Research Facilities
Autologous Stem Cell and Non-Stem Cell Based Therapies Market based on Geography
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa

The market for autologous stem cell and non-stem cell based therapies is examined, and as previously mentioned, market size, trends, and insights are given by nation, type, product, application, and end user.
The United States, Canada, and Mexico in North America; Germany, France, United Kingdom; Netherlands, Switzerland, Belgium; Russia, Italy, Spain, Turkey; Rest of Europe in Europe; China, Japan, India, South Korea; Singapore, Malaysia; Australia, Thailand, Indonesia, Philippines; Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC); Saudi Arabia, United Arab Emirates; South Africa, Egypt, Israel; Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA); Brazil, Argentina, and Rest of South America as a part of South America are the nations included in the market report on autologous stem cell and non-stem cell based therapies.
In terms of market share and revenue, the autologous stem cell and non-stem cell based therapies market is dominated by North America, and this trend is expected to persist throughout the forecast period. This is because numerous infectious ailments are treated in this area with a well-developed healthcare system and low risks associated with the therapy. However, because of the region's advanced healthcare infrastructure, tax laws, and favourable reimbursement policies, Asia-Pacific is expected to grow at the fastest rate during the forecast period.
The country-specific market affecting variables and domestic regulatory changes that affect the market's present and future trends are also provided in the autologous stem cell and non-stem cell based therapies market research. Some of the key indicators utilised to predict the market situation for certain countries are data points like consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, and upstream and downstream value chain analysis. When presenting a forecast analysis of the nation data, factors such as the availability and presence of global brands, the difficulties they encounter from the intense or minimal rivalry from local and domestic brands, the effect of trade routes and domestic tariffs, are also taken into account.
Along with providing you with a detailed market analysis for each country, the autologous stem cell and non-stem cell based therapies market also offers you information on installed bases of various products for the autologous stem cell and non-stem cell based therapies market, the impact of technology using life line curves and changes in healthcare regulatory scenarios, and their implications for the market.
Details by competitor are provided by the market competitive landscape for autologous stem cell and non-stem cell based therapies. The company's overview, financials, revenue, market potential, R&D investment, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance are all included in the details. Only the firms' focus on the market for autologous stem cell and non-stem cell based therapies is shown by the data points above.
Caladrius Biosciences, Inc., Antria Inc., BrainStorm Cell Limited, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Opexa Therapeutics, Inc., Orgenesis Inc, Regeneus Ltd, U.S. Stem Cell, Inc., Castle Creek Biosciences, Inc., Gilead Sciences, Inc., Novartis AG, Takeda Pharmaceutical Company Limited., and NEOSTEM are a few of the prominent market participants involved in autologous stem cell and non-stem cell based therapies.
• This report illustrates the most vital attributes of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market.

ページTOPに戻る

Table of Contents

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Type: Market Size & Analysis
5.1. Overview
5.2. Autologous Stem Cells
5.3. Autologous Non-Stem cells
6. Application: Market Size & Analysis
6.1. Overview
6.2. Application
6.3. Cancer
6.4. Neurodegenerative Disorders
6.5. Cardiovascular Disease
6.6. Orthopedic Diseases
6.7. Other Applications
7. End User: Market Size & Analysis
7.1. Overview
7.2. End user
7.3. Hospitals
7.4. Ambulatory Surgical Centers
7.5. Research Facilities
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. Vericel Corporation
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Dendreon Corporation (Sanpower Group)
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Caladrius Biosciences, Inc.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. BrainStorm Cell Therapeutics
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Regeneus Ltd..
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Genzyme Corporation
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Pluristem Therapeutics Inc
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. U.S. Stem Cell Inc
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. TiGenix (Takeda)
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Fibrocell Science, Inc.
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy

11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 2. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR CONSUMABLES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR AUTOLOGOUS STEM CELLS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR AUTOLOGOUS NON-STEM CELLS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 6. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR APPLICATION, 2021-2030 (USD BILLION)
TABLE 7. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR NEURODEGENERATIVE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR CARDIOVASCULAR DISEASE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR ORTHOPEDIC DISEASES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 13. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR HOSPITALS, 2021-2030 (USD BILLION)
TABLE 14. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR AMBULATORY SURGICAL CENTERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 15. AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE FOR RESEARCH FACILITIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. NORTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 17. NORTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 19. NORTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 20. U.S AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 21. U.S AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 22. U.S AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 23. CANADA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 24. CANADA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 25. CANADA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 26. MEXICO AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 27. MEXICO AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. MEXICO AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 29. EUROPE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 30. EUROPE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 31. EUROPE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 32. EUROPE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 33. GERMANY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 34. GERMANY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 35. GERMANY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 36. U.K AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 37. U.K AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 38. U.K AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 39. FRANCE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 40. FRANCE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 41. FRANCE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 42. ITALY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 43. ITALY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 44. ITALY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 45. SPAIN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 46. SPAIN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 47. SPAIN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 48. ROE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 49. ROE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 50. ROE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 51. ASIA PACIFIC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 53. ASIA PACIFIC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 54. ASIA PACIFIC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 55. CHINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 56. CHINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 57. CHINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 58. INDIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 59. INDIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 60. INDIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 61. JAPAN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 62. JAPAN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 63. JAPAN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 64. REST OF APAC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 65. REST OF APAC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 66. REST OF APAC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 67. LATIN AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 68. LATIN AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 69. LATIN AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 70. BRAZIL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 71. BRAZIL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 72. BRAZIL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 73. ARGENTINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 74. ARGENTINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 75. ARGENTINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 76. MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 77. MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 78. MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 79. SAUDI ARABIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 80. SAUDI ARABIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 81. SAUDI ARABIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 82. UAE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 83. UAE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 84. UAE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 85. REST OF MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 86. REST OF MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 87. REST OF MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 88. FIBROCELL SCIENCE INC.: FINANCIALS
TABLE 89. FIBROCELL SCIENCE INC.: PRODUCTS & SERVICES
TABLE 90. FIBROCELL SCIENCE INC.: RECENT DEVELOPMENTS
TABLE 91. VERICEL CORPORATION: FINANCIALS
TABLE 92. VERICEL CORPORATION: PRODUCTS & SERVICES
TABLE 93. VERICEL CORPORATION: RECENT DEVELOPMENTS
TABLE 94. DENDREON CORPORATION (SANPOWER GROUP): FINANCIALS
TABLE 95. DENDREON CORPORATION (SANPOWER GROUP): PRODUCTS & SERVICES
TABLE 96. DENDREON CORPORATION (SANPOWER GROUP): RECENT DEVELOPMENTS
TABLE 97. CALADRIUS BIOSCIENCES, INC. : FINANCIALS
TABLE 98. CALADRIUS BIOSCIENCES, INC. : PRODUCTS & SERVICES
TABLE 99. CALADRIUS BIOSCIENCES, INC. : RECENT DEVELOPMENTS
TABLE 100. BRAINSTORM CELL THERAPEUTICS: FINANCIALS
TABLE 101. BRAINSTORM CELL THERAPEUTICS: PRODUCTS & SERVICES
TABLE 102. BRAINSTORM CELL THERAPEUTICS: RECENT DEVELOPMENTS
TABLE 103. REGENEUS LTD.: FINANCIALS
TABLE 104. REGENEUS LTD.: PRODUCTS & SERVICES
TABLE 105. REGENEUS LTD.: RECENT DEVELOPMENTS
TABLE 106. GENZYME CORPORATIONFINANCIALS
TABLE 107. GENZYME CORPORATION: PRODUCTS & SERVICES
TABLE 108. GENZYME CORPORATION: DEVELOPMENTS
TABLE 109. PLURISTEM THERAPEUTICS INC: FINANCIALS
TABLE 110. PLURISTEM THERAPEUTICS INC: PRODUCTS & SERVICES
TABLE 111. PLURISTEM THERAPEUTICS INC: RECENT DEVELOPMENTS
TABLE 112. U.S. STEM CELL INC: FINANCIALS
TABLE 113. U.S. STEM CELL INC: PRODUCTS & SERVICES
TABLE 114. U.S. STEM CELL INC: RECENT DEVELOPMENTS
TABLE 115. TIGENIX (TAKEDA): FINANCIALS
TABLE 116. TIGENIX (TAKEDA): PRODUCTS & SERVICES
TABLE 117. TIGENIX (TAKEDA): RECENT DEVELOPMENTS